ミズーリ州における悪性黒色腫の臨床試験
ミズーリ州内の拠点で、悪性黒色腫に関する23件の研究が参加者を募集しています。
ミズーリ州内の都市
- St. Louis21件の研究
- Kansas City10件の研究
- Springfield6件の研究
- O'Fallon5件の研究
- Saint Joseph4件の研究
- Cape Girardeau3件の研究
- Joplin3件の研究
- Columbia3件の研究
公式研究テキスト（英語）
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Washington University Medicine, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- 他21件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Washington University, School of Medicine, St Louis
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06172478BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Saint Francis Medical Center, Cape Girardeau
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- 他4件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05136196A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- VA St. Louis Healthcare System, St Louis
- Washington University School of Medicine, St Louis
- Mercy South, St Louis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06246916Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Cancer Center - Lee's Summit, Lee's Summit
被験者募集中第3相
75歳以上 · 全性別 · 2026/09/24更新 · NCT07068074Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
- Washington University School of Medicine, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT06529822Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Washington University, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT05267626A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- Saint Louis Cancer and Breast Institute-Ballwin, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- 他19件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/15更新 · NCT04511013Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- Washington University School of Medicine, St Louis
- 他2件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/31更新 · NCT05896839Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Washington University School of Medicine, St Louis
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119Project: Every Child for Younger Patients With Cancer
- University of Missouri Children's Hospital, Columbia
- Children's Mercy Hospitals and Clinics, Kansas City
- Cardinal Glennon Children's Medical Center, St Louis
- 他2件
被験者募集中観察研究
25歳以下 · 全性別 · 2026/08/25更新 · NCT02402244A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT07115043IDOV-Immune for Advanced Solid Tumors
- Washington University School of Medicine, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/05更新 · NCT06910657Integrated Cancer Repository for Cancer Research
- Saint Luke's Cancer Institute, East, Kansas City
- Saint Luke's Cancer Institute, Kansas City
- Saint Luke's Cancer Institute, Kansas City North, Kansas City
- 他3件
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Mercy Hospital - SPG, Springfield
- Mercy Hospital - South, St Louis
- Mercy Hospital -STL, St Louis
被験者募集中観察研究
18歳以上 · 全性別 · 2026/06/29更新 · NCT07327489MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
- Saint Louis University Hospital, St Louis
- Washington University of St. Louis, St Louis
被験者募集中第1/2相
18歳〜90歳 · 全性別 · 2026/06/10更新 · NCT05655312Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Saint Louis Cancer and Breast Institute-Ballwin, Ballwin
- Parkland Health Center - Farmington, Farmington
- 他16件
被験者募集中観察研究
18歳以上 · 全性別 · 2026/03/17更新 · NCT06418204Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- Washington University School of Medicine, St Louis
被験者募集中第3相
18歳以上 · 全性別 · 2026/02/25更新 · NCT05549297Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
- Washington University School of Medicine, St Louis
被験者募集中観察研究健康なボランティア歓迎
18歳以上 · 全性別 · 2026/02/20更新 · NCT04354064SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Kansas City
- Massive Bio SYNERGY-AI site, St Louis
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- Siteman Cancer Centre, Barnes Jewish West County, Creve Coeur
- University of Kansas Cancer Center, Kansas City
- Cox South Hospital, Springfield
- 他1件
被験者募集中
18歳以上 · 全性別 · 2024/11/27更新 · NCT03860883ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。